Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nurse-led CV Risk Screening in RA and PsA
NCT03625089Withdrawn
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of atorvastatin in cardiovascular disease (CVD) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Change in Framingham risk score at 12 months. Planned start Sep 2018; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03625089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625089.